A big zzzzz on this beautiful day on the lake, water clear and fish not yet slamming the baits. I see the board is in some semi-hibernative state, but here goes.
Interesting market day as I luckily traded out this morning of my remaining shorter term CARA shares, picked up after the follow on offering at $18. Still hold most but not all of my long term CARA shares.
Recently I became very interested in MDGL. I would urge any readers to check this company out.
madrigalpharma.com
Here are some reasons why I like the company, as I wrote in a note to some friends.
"There are several reasons why I like this novel/emerging biotech company. One is the history of the CEO and his multiple clinical successes (companies, drugs) over the past 25 years, Paul Friedman, the INCY man. Another is the lucrative and unmet medical need space of liver diseases and NASH. Another is the clinical assets of the company, and the lead scientist on the the discovery of these assets (MGL-3196 and follow on compounds), Becky Taub, MD, now running clinical at MDGL. These unique and novel assets come from much past work and intellectual property, and the drug candidates are unique in that they reduce cholesterol and triglycerides, and they are restricted to the liver. Another is that the company has a $200M market cap. Another is that Friedman and Taub are husband and wife team that will use these assets to sail into the sunset of their careers."
Beware MDGL volume is tiny, trades by appointment. Would be interested in comments.. |
